Antipsychotic Drug Market

RECENT NEWS
The Economic Times  Nov 26  Comment 
The pullback came after a series of failures in clinical trials that evaluated anti-depressants and anti-psychotic medications.
Benzinga  Nov 14  Comment 
ACADIA Pharmaceuticals (NASDAQ: ACAD) today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease...
guardian.co.uk  Oct 28  Comment 
Footage from Mangaung Correctional Centre near Bloemfontein, South Africa, shows G4S prison workers apparently administering anti-psychotic drugs to a patient illegally Leah Green
MedPage Today  Aug 22  Comment 
(MedPage Today) -- Antipsychotic medications were linked to type 2 diabetes in children and young adults, particularly with longer use at higher doses, a Medicaid study showed.
MarketWatch  Aug 12  Comment 
U.S. federal health officials are studying whether doctors are prescribing antipsychotic drugs too often to children in the Medicaid system, The Wall Street Journal reported late Sunday. The medications in question include drugs made by...
MedPage Today  Jun 23  Comment 
CHICAGO (MedPage Today) -- Atypical antipsychotics impact metabolic risk independent of weight gain, according to a carefully-controlled laboratory monitoring study.
Sydney Morning Herald  Apr 24  Comment 
Australian of the year Ita Buttrose has accused aged care providers of flouting federal rules by tying residents to beds and chairs and using anti-psychotic drugs to deal with behavioural problems.     
guardian.co.uk  Feb 21  Comment 
Sharp rise in medication, including chemical calming 'cosh', revealed in database study by Queen's University Belfast Prescriptions for psychotropic drugs, including those sometimes referred to as the "chemical cosh", soar amongst elderly people...
MedPage Today  Feb 5  Comment 
(MedPage Today) -- More than one in five U.S. nursing home residents are given antipsychotic medications -- generally off-label, a national analysis revealed.




 
TOP CONTRIBUTORS

Antipsychotics are central nervous system therapies used to treat diseases such as schizophrenia or bipolar disorder. Patients with schizophrenia may hear "voices" or have strange thoughts that are "out of touch" with reality that can hamper their ability to carry out normal day-to-day life.[1] Patients with bipolar disorder are characterized by mood changes that cycle between "high" manic moments and "low" depression moments.[2] Together, the antipsychotic and antimaniac drug markets represent approximately 5 million people and generated revenues of $17.4 billion in 2008, a decline of 4% from 2007 largely driven by increased competition from lower priced generic drugs.[3]

The major players in the antipsychotics market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Johnson & Johnson, and GlaxoSmithKline. Eli Lilly's Zyprexa has the largest market share of the market, at 26% ($4.70 billion), while AstraZeneca's Seroquel, at 2nd place ($4.45 billion) remains the most widely prescribed antipsychotic.[4] Bristol-Myers Squibb's Abilify, which was approved for market release in 2007, saw a 30% growth in sales from 2007 to 2008 to $2.15 billion, making it the fastest growing therapeutic in the antipsychotics market. Moreover, data that Abilify may carry less of a risk for weight gain and diabetes than the incumbent therapies is driving its push for increased market share.[5]

The antipsychotic drug market is treatened by loss of exclusivity from patent expirations. By 2012, four of the six largest antipsychotic therapies will lose their patents and see revenues decreased by generic competition.[6] However, this threat to market size may be offset if Abilify and other novel antipsychotic therapies are shown to carry reduced risks for weight gain and diabetes.

Players in the Antipsychotic and antimaniac drug market

Error creating thumbnail
2008 Revenue of Antipsychotic Drugs (in billions)

Eli Lilly and Company (LLY): Zyprexa

Zyprexa earned revenues of $4.70 billion in 2008, representing 23% of Eli Lilly's total earnings in that year. Total sales for Zyprexa decreased 1% from 2007 to 2008, due to decreased demand from increased generic competition.[7] Zyprexa was approved in 2000 to treat schizophrenia. Eli Lilly's patent for Zyprexa expires on April 23, 2011.[8]

AstraZeneca: Seroquel

Seroquel earned revenues of $4.45 billion in 2008, a growth of 9% from 2007 with sales driven by higher demand.[9] Seroquel was originally approved in 1997 to treat patients with schizophrenia and is available in extended release tablets under the label, Seroquel XR, which only requires once-daily doses.[10] Regulatory submissions are underway to gain approval for Seroquel as a treatment for major depressive disorder and bipolar disorder.[11] As of 2007, Seroquel remains the most commonly prescribed atypical anti-psychotic in the US.[12]

In February of 2009, AstraZeneca came under fire for allegations that they failed to warn physicians that Seroquel carries risks of weight gain and diabetes for prescribed patients. 9,000 lawsuits involving 15,000 patients have been filed regarding this case.[13] AstraZeneca's patent on Seroquel expires on September 26, 2011.[14]

Bristol-Myers Squibb and Otsuka: Abilify

Abilify earned revenues of $2.15 billion in 2008 for a growth of 30% from 2007 to 2008, driven by both higher demand and higher selling prices.[15] Abilify was approved in 2007 as an adjunctive treatment for major depressive disorder as well as a therapeutic for schizophrenia and bipolar disorder in adolescents.[16] BMS's patent on Abilify expires on October 20, 2014.[17]

Johnson & Johnson: Risperdal and Invega

J&J's antipsychotics franchise, including the Risperdal formulations and Invega, earned revenues of $3.8 billion in 2008, a decrease of 24% from 2007 to 2008.[18] Risperdal lost its patent exclusivity in March 2007, and has since seen sales decline substantially.[19]

Invega was approved in 2007 by the FDA to treat schizophrenia.[20] Invega contains a metabolite of the active ingredient of Risperdal in a controlled release formulation[21] and has been criticized as not being any different from its predecessor.[22] J&J retains exclusivity for Invega until April 27, 2010.[23]

GlaxoSmithKline: Lamictal

Lamictal earned revenues of $1.27 billion[24] in 2008 for a decrease of 16% from 2007 to 2008.[25] In June of 2003, Lamictal was approved to treat bipolar disorder in adults, making it the first pharmaceutical since lithium to be approved by the FDA for bipolar disorder.[26]

Lamictal lost its exclusivity in July of 2008[27], and Taro Pharmaceutical's generic version was approved by the FDA in February of 2009.[28] The increased competition will lead to a decrease in sales of Lamictal.

Pfizer: Geodon

Geodon earned revenues of $1.01 billion in 2008 for a growth of 18% from 2007 to 2008. Geodon (marketed outside the U.S. as Zeldox) is approved for the treatment of schizophrenia as well as acute mania and mixed episodes associated with bipolar disorder. Geodon is currently in development to treat Bipolar disorder.[29] Pfizer's patents on Geodon expire on March 2, 2012.[30]

Antipsychotics Market Share by Revenue, 2008
Rank Market Share Company Product Revenue ($ billion) Growth
1 27% Eli Lilly Zyprexa 4.70 (-1%)
2 26% AstraZeneca Seroquel 4.45 9%
3 22% Johnson & Johnson Risperdal 3.8 (-24%)
4 12% Bristol-Meyers Squibb Abilify 2.15 30%
5 7% GlaxoSmithKline Lamictal 1.27 (-16%)
6 6% Pfizer Geodon 1.01 18%



Error creating thumbnail
Antipsychotic Market Share by Prescription[31]

Major Drugs in the Pipeline

  • Bifeprunox (Wyeth and Solvay): Bifeprunox is a partial dopamine agonist in development to treat schizophrenia and bipolar disorder. Bifeprunox is being developed by Solvay Pharmaceuticals and was intended to be marketed by Wyeth in the United States. However, the FDA rejected Solvay's NDA for Bifeprunox in August of 2007. Solvay is still seeking approval in the EU, where it would be marketed by Lundbeck.[32]
  • Saphris (Schering-Plough): Schering-Plough added Saphris to their pipeline with the acquisition of Organon in November of 2007.[33] Saphris is a fast-dissolving psychopharmacologic agent in development to treat patients with schizophrenia and bipolar disorder. Schering-Plough has submitted an NDA for Saphris and is awaiting a decision from the FDA for marketing approval.[34]
  • Fanapt (Vanda Pharmaceuticals): Currently in Phase III clinical trials, Fanapt is a dopamine agonist for the treatment of schizophrenia, bipolar disorders and other psychiatric conditions.[35] Vanda Pharmaceuticals licensed Fanapt from Novartis, and has submitted an NDA for FDA approval.[36]

Side Effects are a Concern with Antipsychotics

In 2003, the FDA required all manufacturers of atypical antipsychotics (including Risperdal, Geodon, Zyprexa, Seroquel, and Abilify) to add a warning to their drug labels that use of such drugs increases risk of hyperglycemia and diabetes mellitus.[37] The risk of weight gain and diabetes among patients receiving atypical antipsychotics has been well documented and has arisen as a significant controversy in the antipsychotic drug market.[38][39]

Abilify, while newer to the market and with fewer studies done of its association with weight gain compared with more incumbent antipsychotics, may carry less of a risk for weight gain.[40] Abilify's emergence in the antipsychotics market as well as the discovery and development of novel antipsychotics that do not carry significant risks for weight gain may offset the decrease in market size due to generics in the antipsychotics market.

Patent Expirations Threaten the Antipsychotics Market

Patent expirations of two blockbuster antipsychotic medications, Risperdal and Lamictal, have already encouraged the appearance of cheap generics on the market.[41] The appearance of generics for a therapeutic introduces competition into the market and substantially drives down the prices of those therapeutics. Several major drugs in the antipsychotic market have patent expiration dates before 2012, including Zyprexa (April 23, 2011), Seroquel (September 26, 2011), and Invega (April 27, 2010). When these therapeutics lose patent exclusivity, generics will offer psychiatrists a wide variety of cheap medications to prescribe, substantially decreasing the size of the antipsychotics market.

Error creating thumbnail
Patent Expiration Dates for Major Antipsychotics on the Market

References

  1. National Institutes of Health: Antipsychotic medications
  2. National Institutes of Health: Antimanic Medications
  3. The Antipsychotics Market Insight & Analysis 2008. Visiongain.
  4. AstraZeneca 2008 10-K Annual Report, p.57
  5. National Alliance on Mental Illness: Abilify Profile
  6. FDA Orange Book
  7. Eli Lilly 2008 10-K Annual Report, p.23
  8. FDA Orange Book: Zyprexa
  9. AstraZeneca 2008 20-F Annual Report, p.4
  10. AstraZeneca 2008 20-5 Annual Report, p.21
  11. AstraZeneca 2008 20-F Annual Report, p.29
  12. AstraZeneca 2007 10-K Annual Report, p.57
  13. Reuters: AstraZeneca downplayed Seroquel risks, lawyers say
  14. FDA Orange Book: Seroquel
  15. BMS 2008 10-K Annual Report, p.4
  16. BMS 2008 10-K Annual Report, p.8
  17. FDA Orange Book: Abilify
  18. Johnson & Johnson 2008 10-K Annual Report, p.36
  19. Johnson & Johnson 2008 10-K Annual Report, p.36
  20. Johnson & Johnson 2007 10-K Annual Report, p.26
  21. Invega (paliperidone), Son of Risperdal (risperidone), Wins FDA Okay for Schizophrenia
  22. Invega: Can You Say "Patent Extender?"
  23. FDA Orange Book: Invega
  24. Converted from £926 million using a 1.37 pound to dollar conversation factor (British Pound Currency Exchange Forecast)
  25. GlaxoSmithKline 2008 20-F Annual Report, p.35
  26. Lamotrigine Drug Information
  27. FDA Orange Book: Lamictal
  28. Taro's ANDA for seizure drug wins FDA approval
  29. Pfizer 2008 10-K Annual Report, p.2
  30. FDA Orange Book: Geodon
  31. Cowen and Company. Therapeutic Categories Outlook. March 2008.
  32. Drug Development Technology: Bifeprunox
  33. Schering-Plough Completes Acquisition of Organon BioSciences
  34. Schering-Plough Submits Response to FDA for SAPHRIS
  35. Vanda: Development Pipeline
  36. Vanda Pharmaceuticals submits iloperidone NDA
  37. Psychiatry Online: FDA to Require Diabetes Warning On Antipsychotics
  38. MayoClinic Online: Antipsychotic medications: Is weight gain inevitable?
  39. Atypical antipsychotics and weight gain--a systematic review
  40. National Alliance on Mental Illness: Abilify Profile
  41. Taro's ANDA for seizure drug wins FDA approval
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki